All authors have contributed as follows: SM 25% writing, XS 25% writing, MB 10% writing, DS 15% writing, and JPM 25% writing. SM, XS and JPM wrote the first draft of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
Not applicable.
Funding
Serge Mignani and Xiangyang Shi were granted by FCT-Fundação para a Ciência e a Tecnologia (Base Fund UIDB/00674/2020 and Programmatic Fund UIDP/00674/2020, Portuguese Government Funds) and ARDITI-Agência Regional para o Desenvolvimento da Investigação Tecnologia e Inovação through the project M1420-01-0145-FEDER-000005-CQM + (Madeira 14–20 Program). Xiangyang Shi, Serge Mignani and Jean-Pierre Majoral were granted by the PRC NSFC-CNRS 2019 (21911530230 for Xiangyang Shi and 199,675 for Serge Mignani and Jean-Pierre Majoral). Jean-Pierre Majoral was granted by the CNRS for financial support. Dzmitry Shcharbin was granted by the NAWA International Academic Partnership Programme EUROPARTNER, PPI/APM/2018/1/00007/U/001, by the State Comission of Science and Technology of Belarus: projects B20SLKG-002, B21TUB-001, B21KORG-001, B21ARMG-002. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]
Xu J, Mao W. Overview of research and development for anticancer drugs. J Cancer Ther. 2016;7:762–72. [DOI]
Prudhomme M, editor. Advances in anticancer agents in medicinal chemistry. Volume 1. Sharjah: Bentham Science Publishers; 2013. [DOI]
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther.2021;6:201. [DOI] [PubMed] [PMC]
Challener CA. New drug-delivery methods: from concept to patient. BioPharm Int. 2016;29:14–8.
Tyson JJ, Novak B. Control of cell growth, division and death: information processing in living cells. Interface Focus. 2014;4:20130070. [DOI] [PubMed] [PMC]
Wang P, Zhou Y, Richards AM. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. Theranostics. 2021;11:8771–96. [DOI] [PubMed] [PMC]
Ahmadzada T, Reid G, McKenzie DR. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev.2018;10:69–86. [DOI] [PubMed] [PMC]
Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther.2020;5:101. [DOI] [PubMed] [PMC]
Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules.2020;25:2692. [DOI] [PubMed] [PMC]
Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer.2021;20:55. [DOI] [PubMed] [PMC]
Silva J, Fernandes AR, Baptista PV. Application of nanotechnology in drug delivery. IntechOpen; 2014. [DOI]
Seigneuric R, Markey L, Nuyten DS, Dubernet C, Evelo CT, Finot E, et al. From nanotechnology to nanomedicine: applications to cancer research. Curr Mol Med.2010;10:640–52. [DOI] [PubMed]
Mignani S, Majoral JP. Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview. New J Chem.2013;37:3337–57. [DOI]
Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005;57:2177–202. [DOI] [PubMed]
Franiak-Pietryga I, Ziemba B, Messmer B, Skowronska-Krawczyk D. Dendrimers as drug nanocarriers: the future of gene therapy and targeted therapies in cancer. In: Simonescu CM, editor. Dendrimers: fundamentals and applications. IntechOpen; 2018. [DOI]
Mignani S, El Kazzouli S, Bousmina M, Majoral JP. Dendrimer space concept for innovative nanomedicine: a futuristic vision for medicinal chemistry. Prog Polym Sci. 2013;38:993–1008. [DOI]
Mignani S, Rodrigues J, Tomas H, Roy R, Shi X, Majoral JP. Bench-to-bedside translation of dendrimers: reality or utopia? A concise analysis. Adv Drug Deliv Rev. 2018;136–137:73–81. [DOI] [PubMed]
Tomalia DA, Fréchet JMJ. Discovery of dendrimers and dendritic polymers: a brief historical perspective. Inc J Polym Sci Part A: Polym Chem. 2020;40:2719–28. [DOI]
Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade AM, et al. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev.2018;47:514–32. [DOI] [PubMed]
Mignani S, Shi X, Ceña V, Shcharbin D, Bryszewska M, Majoral JP. In vivo therapeutic applications of phosphorus dendrimers: state of the art. Drug Discov Today. 2021;26:677–89. [DOI] [PubMed]
Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, et al. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med. 2011;3:81ra35. [DOI] [PubMed]
Mignani S, Tripathi VD, Soam D, Tripathi RP, Das S, Singh S, et al. Safe polycationic dendrimers as potent oral in vivo inhibitors of Mycobacterium tuberculosis: a new therapy to take down tuberculosis. Biomacromolecules. 2021;22:2659–75. [DOI] [PubMed]
Milowska K, Grochowina J, Katir N, El Kadib A, Majoral JP, Bryszewska M, et al. Viologen-phosphorus dendrimers inhibit α-synuclein fibrillation. Mol Pharm.2013;10:1131–7. [DOI] [PubMed]
Solassol J, Crozet C, Perrier V, Leclaire J, Béranger F, Caminade AM, et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol.2004;85:1791–9. [DOI] [PubMed]
Mignani SM, El Brahmi N, El Kazzouli S, Laurent R, Ladeira S, Caminade AM, et al. Original multivalent gold(III) and dual gold(III)-copper(II) conjugated phosphorus dendrimers as potent antitumoral and antimicrobial agents. Mol Pharm. 2017;14:4087–97. [DOI] [PubMed]
Mignani S, Rodrigues J, Tomas H, Caminade AM, Laurent R, Shi X, et al. Recent therapeutic applications of the theranostic principle with dendrimers in oncology. Sci China Mater.2018;61:1367–86. [DOI]
Tarach P, Janaszewska A. Recent advances in preclinical research using PAMAM dendrimers for cancer gene therapy. Int J Mol Sci.2021;22:2912. [DOI] [PubMed] [PMC]
Thapa B, Narain R. Mechanism, current challenges and new approaches for non viral gene delivery. In: Narain R, editor. Polymers and nanomaterials for gene therapy. Woodhead Publishing; 2016. pp. 1–27. [DOI]
Hou W, Wei P, Kong L, Guo R, Wang S, Shi X. Partially PEGylated dendrimer-entrapped gold nanoparticles: a promising nanoplatform for highly efficient DNA and siRNA delivery. J Mater Chem B.2016;4:2933–43. [DOI] [PubMed]
Tros de Ilarduya C, Sun Y, Düzgüneş N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40:159–70. [DOI] [PubMed]
Byk G, Dubertret C, Escriou V, Frederic M, Jaslin G, Rangara R, et al. Synthesis, activity, and structure–activity relationship studies of novel cationic lipids for DNA transfer. J Med Chem. 1998;41:229–35. [DOI] [PubMed]
Wang K, Yan X, Cui Y, He Q, Li J. Synthesis and in vitro behavior of multivalent cationic lipopeptide for DNA delivery and release in HeLa cells. Bioconjug Chem.2007;18:1735–8. [DOI] [PubMed]
Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. Methods Mol Biol.2008;433:159–75. [DOI] [PubMed]
Cao Y, Liu X, Peng L. Molecular engineering of dendrimer nanovectors for siRNA delivery and gene silencing. Front Chem Sci Eng.2017;11:663–75. [DOI]
Dong Y, Yu T, Ding L, Laurini E, Huang Y, Zhang M, et al. A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy. J Am Chem Soc. 2018;140:16264–74. [DOI] [PubMed]
Imamura M, Kodama Y, Higuchi N, Kanda K, Nakagawa H, Muro T, et al. Ternary complex of plasmid DNA electrostatically assembled with polyamidoamine dendrimer and chondroitin sulfate for effective and secure gene delivery. Biol Pharm Bull.2014;37:552–9. [DOI] [PubMed]
Cooper RC, Yang H. Duplex of polyamidoamine dendrimer/custom-designed nuclear-localization sequence peptide for enhanced gene delivery. Bioelectricity. 2020;2:150–7. [DOI] [PubMed] [PMC]
Dzmitruk V, Apartsin E, Ihnatsyeu-Kachan A, Abashkin V, Shcharbin D, Bryszewska M. Dendrimers show promise for siRNA and microRNA therapeutics. Pharmaceutics.2018;10:126. [DOI] [PubMed] [PMC]
Caminade AM, Turrin CO, Majoral JP, editors. Phosphorous dendrimers in biology and nanomedicine: syntheses, characterization, and properties. Singapore: Pan Stanford Publishing Pte Ltd; 2018. [DOI]
Chen L, Li J, Fan Y, Qiu J, Cao L, Laurent R, et al. Revisiting cationic phosphorus dendrimers as a nonviral vector for optimized gene delivery toward cancer therapy applications. Biomacromolecules. 2020;21:2502–11. [DOI] [PubMed]
Ihnatsyeu-Kachan A, Dzmitruk V, Apartsin E, Krasheninina O, Ionov M, Loznikova S, et al. Multi-target inhibition of cancer cell growth by siRNA cocktails and 5-fluorouracil using effective piperidine-terminated phosphorus dendrimers. Colloids Interfaces.2017;1:6. [DOI]
Ionov M, Lazniewska J, Dzmitruk V, Halets I, Loznikova S, Novopashina D, et al. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (A). Mechanisms of interaction. Int J Pharm. 2015;485:261–9. [DOI] [PubMed]
Dzmitruk V, Szulc A, Shcharbin D, Janaszewska A, Shcharbina N, Lazniewska J, et al. Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action. Int J Pharm. 2015;485:288–94. [DOI] [PubMed]
Maksimenko AV, Mandrouguine V, Gottikh MB, Bertrand JR, Majoral JP, Malvy C. Optimisation of dendrimer-mediated gene transfer by anionic oligomers. J Gene Med. 2003;5:61–71. [DOI] [PubMed]
Shcharbin D, Dzmitruk V, Shakhbazau A, Goncharova N, Seviaryn I, Kosmacheva S, et al. Fourth generation phosphorus-containing dendrimers: prospective drug and gene delivery carrier. Pharmaceutics.2011;3:458–73. [DOI] [PubMed] [PMC]
Jain A, Mahira S, Majoral JP, Bryszewska M, Khan W, Ionov M. Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer. J Biomed Mater Res A. 2019;107:1933–44. [DOI] [PubMed]
Shakhbazau AV, Shcharbin DG, Goncharova NV, Seviaryn IN, Kosmacheva SM, Kartel NA, et al. Neurons and stromal stem cells as targets for polycation-mediated transfection. Bull Exp Biol Med.2011;151:126–9. [DOI] [PubMed]
Bohr A, Tsapis N, Andreana I, Chamarat A, Foged C, Delomenie C, et al. Anti-inflammatory effect of anti-TNF-α siRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model. Biomacromolecules. 2017;18:2379–88. [DOI] [PubMed]
Mignani S, Shi X, Guidolin K, Zheng G, Karpus A, Majoral JP. Clinical diagonal translation of nanoparticles: case studies in dendrimer nanomedicine. J Control Release. 2020;337:356–70. [DOI] [PubMed]
Mignani S, Shi X, Rodrigues J, Tomas H, Karpus A, Majoral JP. First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: lessons learned moving forward. Eur J Med Chem. 2021;219:113456. [DOI] [PubMed]
